Overview of the pathological results and treatment characteristics in the first 1000 patients randomized in the SERC trial: axillary dissection versus no axillary dissection in patients with involved sentinel node

Table 4 Multivariate analysis of factors associated with chemotherapy administration in hormone-receptor positive patients

Effect	P value	Contrast	Odd Ratio Estimate	95% CI	P value
Age in class	<.0001	41–75 vs > 75	13.894	[5.050; 38.228]	<.0001
Age in class		<=40 vs > 75	75.801	[14.803; 388.145]	<.0001
Tumor Size	0.0017	10–30 vs < =10	2.724	[1.567; 4.737]	0.0004
Tumor Size		> 30 vs < =10	2.654	[1.060; 6.646]	0.0372
LVI	0.0036	Pos. Vs Neg.	2.163	[1.287; 3.634]	0.0036
HER2 Status	0.0470	Pos. Vs Neg.	3.120	[1.015; 9.588]	0.0470
Histology Type	0.0930	Mixed/Other vs lobular	1.866	[0.716; 4.863]	0.2020
Histology Type		Ductal vs lobular	2.096	[1.077; 4.077]	0.0293
SBR Grade	<.0001	Gr II vs Gr I	3.052	[1.875; 4.967]	<.0001
SBR Grade		Gr III vs Gr I	25.946	[10.448; 64.435]	<.0001
Nb Involved SN	0.4193	> 2 vs < =2	2.635	[0.251; 27.672]	0.4193
SN Status	<.0001	Macro vs ITC	3.695	[1.571; 8.692]	0.0027
SN Status		Micro vs ITC	1.447	[0.603; 3.474]	0.4078
Surgery	0.2921	Conservative vs Mastectomy	0.715	[0.382; 1.335]	0.2921
Hormonotherapy	0.6144	Yes vs No	1.429	[0.357; 5.721]	0.6144
Radiotherapy	0.3787	Yes vs No	1.636	[0.547; 4.899]	0.3787
ALND status	0.5602	Yes vs No	0.881	[0.574; 1.350]	0.5602

Abbreviations: ALND axilliary lymph node dissection, SLNB sentinel lymph node dissection alone, CI confidence interval

ISSN: 1471-2407